Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome  被引量:2

在线阅读下载全文

作  者:Shuang Liu Chen Li Ming-Wei Tang Wen-Shuai Xu Ke-Qi Chen Xin Sui Xin-Lun Tian Kai-Feng Xu 

机构地区:[1]School of Clinical Medicine,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100005,China [2]Department of Traditional Chinese Medicine,Chinese Academy of Medical Sciences&Peking Union Medical College Hospital,Beijing 100730,China [3]Department of Respiratory and Critical Care Medicine,Chinese Academy of Medical Sciences&Peking Union Medical College Hospital,Beijing 100730,China [4]Department of Radiology,Chinese Academy of Medical Sciences&Peking Union Medical College Hospital,Beijing 100730,China

出  处:《Chinese Medical Journal》2019年第19期2378-2379,共2页中华医学杂志(英文版)

摘  要:To the Editor:Lymphangioleiomyomatosis(LAM)is a rare multi-systemic disease that predominantly affects women and is associated with cystic lung destruction,chylous fluid accumulation,and abdominal tumors.[1]The lung function of LAM patients declines at two to four or more times faster rates than the typical age-related decline.Although the mammalian target of rapamycin(mTOR)inhibitor has shown certain benefits for patients with LAM,treatment options remain limited.[2]Synovitis,acne,pustulosis,hyperostosis,and osteitis(SAPHO)syndrome is a spectrum of heterogeneous diseases characterized by osteoarticular and dermatological manifestations.Nonsteroidal anti-inflammatory drugs(NSAIDs),disease-modifying anti-rheumatic drugs,bisphosphonates,and intra-articular steroids are frequently prescribed but are often insufficient to control disease progression.

关 键 词:drugs lung TREATMENT 

分 类 号:R73[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象